Lotus submits NDA for VIZZ in South Korea to treat presbyopia
The NDA submission is based on findings from three randomised, double-masked, controlled Phase III studies carried out in the US.
Drug Development
Eisai seeks PMDA approval for subcutaneous Leqembi in Japan
US FDA approves Lupin’s Armlupeg injection
IASO Bio gains Hong Kong approval for Fucaso application
MHRA approves Roche’s inavolisib for breast cancer
BeOne’s sonrotoclax gains priority FDA review for mantle cell lymphoma
Corstasis Therapeutics partners CVL for Enbumyst integration
UNICEF and Gavi to widen affordable malaria vaccine access
